![]() |
![]() |
(17Β)-17-Hydroxy-17-methylandrost-4-en-3-one (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-on (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one 17-Methyltestosteron 17α-Methyl-3-oxo-4-androsten-17Β-ol 17α-Methyltestosterone Android Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17Β)- Androst-4-en-3-one, 17Β-hydroxy-17-methyl- Dumogran EINECS 200-366-3 Hormale Malogen Masenone MESTERONE METANDREN METHYL TESTOSTERONE methyltestosterone methyl-testosterone Metrone MFCD00003655 mtmucorettes Neo-Hombreol-M Neo-Homobreol (M) NSC-9701 Nu-man Oraviron ORETON METHYL Syndren Testbormona Testora Testosterone, 17-methyl- Testred
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | TDLo | oral | 39mg/kg/33W-I (39mg/kg) | LIVER: "JAUNDICE, CHOLESTATIC" | American Journal of Gastroenterology. Vol. 82, Pg. 461, 1987. |
mouse | LD50 | intraperitoneal | 400mg/kg (400mg/kg) | Drugs in Japan Vol. 6, Pg. 830, 1982. | |
mouse | LD50 | oral | 1860mg/kg (1860mg/kg) | Drugs in Japan Vol. 6, Pg. 830, 1982. | |
mouse | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | Drugs in Japan Vol. 6, Pg. 830, 1982. | |
rat | LD50 | intraperitoneal | 1050mg/kg (1050mg/kg) | Drugs in Japan Vol. 6, Pg. 830, 1982. | |
rat | LD50 | oral | 2500mg/kg (2500mg/kg) | Drugs in Japan Vol. 6, Pg. 830, 1982. | |
rat | LD50 | subcutaneous | 5gm/kg (5000mg/kg) | Drugs in Japan Vol. 6, Pg. 830, 1982. |
Carcinogenicity, Category 1B
Reproductive toxicity, Category 2
Pictogram(s) | ![]() |
---|---|
Signal word | Danger |
Hazard statement(s) | H350 May cause cancer H361 Suspected of damaging fertility or the unborn child |
Precautionary statement(s) | |
Prevention | P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/protective clothing/eye protection/face protection. |
Response | P308+P313 IF exposed or concerned: Get medical advice/ attention. |
Storage | P405 Store locked up. |
Disposal | P501 Dispose of contents/container to ... |
none
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
![]() |
Literatures:
Bi, Honggang; Masse, Robert; Just, George Steroids, 1992 , vol. 57, # 7 p. 306 - 312 ![]() Yield: ~0% |